Poor
Not Aligned
Patient Risk:
Medium
Summary
Most claims are about hydralazine-induced lupus-like syndrome and general DIL epidemiology/risk factors; however, the provided BiDil label excerpts only support that hydralazine hydrochloride has been reported to cause a drug-induced SLE (SLE syndrome) that regresses after discontinuation. The majority of other lupus-related details are not supported by the supplied label text, and no supporting label excerpts were provided for specific indications (HTN, CHF) beyond BiDil’s heart failure indication.
Category Scores
Accurate Statements
Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome.
BiDil label excerpt 5.2 Systemic Lupus Erythematosus: “Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome. Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.”
The increased risk of hydralazine-induced lupus-like syndrome is particularly associated with patients with a history of lupus.
No supporting label text provided in the excerpts for a prior-lupus-specific risk enrichment.
Management of suspected DIL includes discontinuing the offending medication.
BiDil label excerpt 5.2: “Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.” (Supports improvement after discontinuation, but does not explicitly state “management includes discontinuing.”)
Unsupported Statements
Hydralazine is used to treat high blood pressure.
No support in the provided BiDil label excerpts; only BiDil heart failure indication is present.
Hydralazine is used to treat congestive heart failure.
No indication text for hydralazine as monotherapy; provided label excerpts only address BiDil for heart failure.
The increased risk of hydralazine-induced lupus-like syndrome is particularly associated with patients who are prone to developing autoantibodies.
No such risk-factor details present in the supplied label excerpt 5.2.
Drug-induced lupus (DIL) can occur in patients taking certain medications, including hydralazine.
The label excerpt supports hydralazine reporting drug-induced SLE, but the broader generalized DIL framing (“certain medications, including hydralazine”) is not directly supported by the provided excerpt wording.
Drug-induced lupus (DIL) is characterized by the presence of autoantibodies against the body’s own tissues.
No autoantibody characterization present in the provided label excerpts.
DIL is characterized by the presence of autoantibodies against nucleic acids such as double-stranded DNA (dsDNA) and histone.
No dsDNA/histone description present in the supplied label excerpt.
DIL can present with symptoms similar to those of systemic lupus erythematosus (SLE), including joint pain.
Label excerpt 5.2 does not list specific symptom types such as joint pain.
DIL can present with symptoms similar to those of systemic lupus erythematosus (SLE), including fatigue.
No fatigue description present in the supplied label excerpt.
DIL can present with symptoms similar to those of systemic lupus erythematosus (SLE), including skin rashes.
No skin rash description present in the supplied label excerpt.
The incidence of DIL is estimated to be between 1 and 10 cases per million people per year.
No incidence/rate estimate present in the supplied label excerpts.
Hydralazine is associated with an increased risk of DIL, particularly at high doses.
No dose-response (e.g., “high doses”) statement present in the supplied label excerpt 5.2.
Hydralazine is associated with an increased risk of DIL in patients with a history of lupus.
No such subgroup risk statement present in the supplied label excerpt.
Age is a risk factor for DIL, with DIL being more common in older adults.
No age/risk-factor data present in supplied label excerpts.
Sex is a risk factor for DIL, with women more likely to develop DIL than men.
No sex/risk-factor data present in supplied label excerpts.
Race is a risk factor for DIL, with African Americans at higher risk.
No race-specific risk factor data present in supplied label excerpts.
Previous exposure to medications is a risk factor for DIL, including a history of using hydralazine.
No prior-exposure risk-factor statement present in supplied label excerpts.
Genetic predisposition is a risk factor for DIL, with a family history of lupus or autoimmune disorders at higher risk.
No genetic/family-history risk-factor statement present in supplied label excerpts.
Discontinuation of the offending medication may not resolve all symptoms of DIL.
The label excerpt states symptoms and signs usually regress when discontinued; it does not support “may not resolve all symptoms.”
Treatment of DIL typically involves corticosteroids.
No treatment regimen guidance (corticosteroids) present in supplied label excerpts.
Treatment of DIL sometimes involves immunosuppressive agents.
No immunosuppressive treatment guidance present in supplied label excerpts.
In rare cases, DIL may progress to SLE-like disease.
No progression risk statement present in supplied label excerpts.
Contradictions
Low
AI Statement
Discontinuation of the offending medication may not resolve all symptoms of DIL.
Label Reference
BiDil label excerpt 5.2: “Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.”
Important Omissions
For the evaluated lupus-related warning, the label excerpt does not describe DIL autoantibodies, specific symptom list (e.g., joint pain/fatigue/rash), incidence rates, or risk-factor stratification; those material details were asserted but are not supported. Corresponding label-supported elements (that symptoms/signs usually regress after discontinuation) were not consistently reflected with precision.
Importance:
Moderate
No BiDil-specific indication/dosing statements were provided in the user’s claim list (these were instead general hydralazine statements). Material BiDil on-label context (BiDil indicated for heart failure as adjunct in self-identified black patients) was omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Over half of the claims are unsupported by the supplied BiDil label excerpts and introduce unverified risk factors/epidemiology and treatment/progression assertions; additionally, an imprecise statement conflicts with the label’s “usually regress” phrasing after discontinuation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most lupus/DIL mechanistic, epidemiologic, and management/progression claims are not supported by the provided FDA label excerpts; only the general existence of hydralazine-reported drug-induced SLE syndrome with regression after discontinuation is supported.
Suggested Improvement
Limit claims to what the provided label excerpt supports (hydralazine hydrochloride reported to cause drug-induced SLE syndrome; symptoms/signs usually regress with discontinuation). Remove unsupported statements about incidence rates, specific autoantibodies (dsDNA/histone), symptom specifics (joint pain/fatigue/rash), dosing-specific risk, demographic risk-factor stratification, and treatment/progression assertions not present in the excerpts.